Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Innate Pharma SA

< Previous 1 2 3 4 Next >
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Its Participation in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Its Participation to Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Its Participation to Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Leadership Change
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Host Virtual KOL Event on Lacutamab
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Its Participation to Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma 2024 Financial Calendar
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Provides Update on Lacutamab Clinical Program
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.